The busiest recruitment category in clinical research — what these studies involve, who qualifies, and why the newest drug is only available inside a trial.
Weight loss is currently the most active category in clinical trial recruitment, driven by the GLP-1 class of medications — semaglutide, tirzepatide, and the pipeline behind them. Sponsors are running studies on new molecules, new doses, oral versions, combination therapies, and long-term outcomes, which means sites across the country need participants on an ongoing basis.
The category has a distinctive draw beyond compensation: some compounds are available only inside a trial. Retatrutide is not FDA approved — the only way anyone receives it today is as a clinical trial participant. This guide covers how weight loss studies actually run, who qualifies, the approved-versus-experimental distinction that shapes your options, and the honest trade-offs to weigh before screening.
The GLP-1 drugs changed the economics of obesity treatment, and every sponsor wants a position: better efficacy, easier dosing, oral formulations, fewer side effects, or the next mechanism entirely. That competition translates directly into recruitment volume — dose-finding studies, head-to-head comparisons, maintenance studies, and trials in related conditions from sleep apnea to heart health, all enrolling simultaneously.
For participants, volume means access. Unlike narrow rare-disease protocols, weight loss trials recruit from a broad population, and sites in major metros — Dallas and Los Angeles among the busiest — often run several concurrently. It is one of the few categories where being screened out of one study frequently means being offered another at the same site.
The distinction that shapes everything: semaglutide and tirzepatide are FDA approved — available by prescription, which means joining a trial is not the only path to them, though trials testing new doses, formulations, and combinations of approved drugs still recruit heavily. Prescription access has its own barrier, cost, and it is substantial; this breakdown of what semaglutide actually costs with and without coverage shows why many people explore trials in the first place.
Retatrutide is different: it is not FDA approved, and clinical trials are the only way to receive it. No pharmacy, no telehealth service, no compounding operation can legally provide it — any website claiming otherwise is selling something mislabeled at best. For an unapproved molecule, the trial is not a discount channel; it is the entire channel, with study medication provided at no cost to participants, as in every legitimate trial. That reality is a major reason retatrutide studies fill quickly despite demanding schedules.
A typical GLP-1 trial is a long outpatient commitment: a year or more of scheduled visits. After screening — medical history, labs, BMI verification — and consent, you are randomized, often into a double-blind design where a placebo arm is possible. Visits involve weigh-ins, vitals, blood draws, ECGs, and side effect reviews; between visits you inject the study medication (or placebo) weekly at home and may log food, symptoms, or device data.
Expect lifestyle components too: many protocols include standardized diet and activity counseling for every arm, since the drugs are studied on top of lifestyle change, not instead of it. Side effects in this class are well documented — nausea and digestive complaints lead the list, especially during dose escalation — and the consent document details them. Compensation follows outpatient norms: per-visit payments plus travel reimbursement, in the modest range typical of studies where participants may also derive treatment benefit — not Phase 1 confinement money, as our pay guide explains.
Join the free email alert — we watch the NIH registry weekly so you don't have to.
Get trial alertsInclusion typically centers on BMI: obesity-range BMI, or overweight-range BMI plus a weight-related condition such as high blood pressure or prediabetes. Some trials specifically want participants with type 2 diabetes; others specifically exclude it — read each listing. Common exclusions: recent use of GLP-1 medications (a class-specific washout applies), personal or family history of certain thyroid cancers, pancreatitis history, pregnancy or plans for it, and recent weight loss surgery.
Two honest notes. First, current GLP-1 users usually cannot enroll without a washout — trials need a clean baseline, and switching from prescription to trial specifically to access a newer drug is a decision to discuss with your physician, not a shortcut to take alone. Second, the standard rule applies with extra force here: never misstate weight history, medications, or conditions to qualify. Eligibility criteria in this class exist around real risks, and screening exists to protect you — the theme of our qualifying guide.
The appeal is real: access to closely monitored care, labs and check-ins at no cost, possible access to a next-generation molecule, and per-visit compensation. The costs are equally real: a placebo possibility in many designs, a year-plus commitment, documented side effects, and protocol rules governing your diet, medications, and other treatments for the duration.
Questions worth asking the study team before consenting: What is the placebo probability? What happens at study end — is there an open-label extension where every participant receives the active drug? What weight loss support does the placebo arm receive? What are the discontinuation rules if side effects are hard? And as with every study in this directory, verify the trial on ClinicalTrials.gov, confirm IRB oversight, and take the consent document home before signing. Whether or not this category fits you, that checklist is the constant.
Get an email when a new clinical trial starts recruiting within 30 miles of your ZIP code. No spam — only real studies from the NIH registry.